アナセトラピブ 価格 もっと(7)

メーカー	製品番號(hào)	製品説明	CAS番號(hào)	包裝	価格	更新時(shí)間	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01COBQE-9719	アナセトラピブ Anacetrapib	875446-37-0	250mg	￥42500	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01COBQE-9719	アナセトラピブ Anacetrapib	875446-37-0	1g	￥95000	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01COBQE-9719	アナセトラピブ Anacetrapib	875446-37-0	5g	￥290000	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01MAS112674	(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one	875446-37-0	1g	￥331200	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01COBQE-9719	アナセトラピブ Anacetrapib	875446-37-0	10g	￥505000	2024-03-01	購入

アナセトラピブ 化學(xué)特性,用途語,生産方法

効能

アテローム硬化性疾患治療薬, コレステリルエステル転送タンパク阻害薬

使用

An orally active and potent cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis, in particular dyslipidemia.

酵素阻害剤

This cholesteryl ester transfer protein (or CETP) inhibitor (FW = 637.51 g/mol; CAS 875446-37-0), also known by the code name MK-0859, reduces plasma cholesterol concentrations, thereby increasing serum highdensity lipoprotein levels and preventing cardiovascular disease associated with hypercholesteremia. X-ray crystal studies suggest that CETP is a crescent-shaped protein with a 6-nm hydrophobic tunnel traversing its core Both of the tunnel’s two entrances face the protein’s concave surface, which most likely is the interaction platform for binding HDL particles and engaging its lipoprotein constituents. CETP mediates the reciprocal transfer of neutral lipids (e.g., cholesteryl esters and triglycerides) and phospholipids between different lipoprotein fractions in blood plasma. Anacetrapib is unlike many CETP inhibitors, which increase systolic blood pressure. Anacetrapib also exhibits a low-to-moderate degree of absorption after oral dosing and majority of the absorbed dose is eliminated via oxidation to a series of hydroxylated metabolites that undergo conjugation with glucuronate before excretion into bile. Unlike torcetrapib, another CETP inhibitor, anacetrapib does not elevate blood pressure, alter electrolytes, or cause any significant side effects.

アナセトラピブ 上流と下流の製品情報(bào)

原材料

準(zhǔn)備製品

アナセトラピブ 生産企業(yè)

名前	電話番號(hào)	電子メール	國籍	製品カタログ	優(yōu)位度
Seasons Biotechnology Co., Ltd.	+86-0576-89232655 +86-13566878689	info@seasonsbio.com	China	47	58
Hebei Yanxi Chemical Co., Ltd.	+86-17531190177	faithe@yan-xi.com	China	5853	58
Hebei Chuanghai Biotechnology Co., Ltd	+86-17732866630	mina@chuanghaibio.com	China	18126	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +86-15965530500	nickzhang@hangyubiotech.com	China	9942	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29640	60
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21585	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29812	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58
Hangzhou Cyanochem Co., Ltd.	+86 17788583750	sales@cyanochem.com	CHINA	281	58

875446-37-0(アナセトラピブ)キーワード:

---

• 875446-37-0
• (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one
• Anacetrapib
• Mk0859
• Mk-0859
• Unii-p7T269pr6s
• (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one
• Anacetrapib(MK0859)
• 2-Oxazolidinone, 5-[3,5-bis(trifluoroMethyl)phenyl]-3-[[4'-fluoro-2'-Methoxy-5'-(1-Methylethyl)-4-(trifluoroMethyl)[1,1'-biphenyl]-2-yl]Methyl]-4-Methyl-, (4S,5R)-
• (4S,5R)-5-[3,5-Bis(trifluoroMethyl)phenyl]-3-[[4'-fluoro-2'-Methoxy-5'-(1-Methylethyl)-4-(trifluoroMethyl)[1,1'-biphenyl]-2-yl]Methyl]-4-Methyl-2-oxazolidinone
• (4S,5R)-5-[3,5-Bis(trifluoroMethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-Methoxy-4
• (4S,5R)-5-(3,5-bis(trifluoroMethyl)phenyl)-3-((4'-fluoro-2'-Methoxy-4-(trifluoroMethyl)-[1,1'-biphenyl]-2-yl)Methyl)-4-Methyloxazolidin-2-one
• (4S,5R)-5-(3,5-bis(trifluoroMethyl)phenyl)-3-((4-fluoro-5-isopropyl-2-Methoxy-4-(trifluoroMethyl)-[1,1-biphenyl]-2-
• Anacetripib
• (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one Anacetrapib (MK-0859)
• (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one
• EZSolution Anacetrapib
• Anacetrapib, >=99%
• (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one
• (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-
• MK0859; MK-0859; MK 0859; ANACETRAPIB
• CS-66
• MK-0859; MK 0859; MK0859
• Anacetrapib USP/EP/BP
• (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-...
• Anacetrapib 13C6
• TIANFUCHEM-- Anacetrapib
• (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-5-isopropyl-2-methoxy-phenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-oxazolidin-2-one
• Anacetrapib, 10 mM in DMSO
• (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-biphenyl-2-yl)methyl)-4-methyl-oxazolidin-2-one
• Timapiprant
• アナセトラピブ
• アナセトラピブ (JAN)
• (4S,5R)-5-[3,5-ビス(トリフルオロメチル)フェニル]-3-[[4′-フルオロ-2′-メトキシ-5′-イソプロピル-4-(トリフルオロメチル)ビフェニル-2-イル]メチル]-4-メチル-2-オキサゾリジノン
• (4S,5R)-5-[3,5-ビス(トリフルオロメチル)フェニル]-3-{[4'-フルオロ-2'-メトキシ-5'-(プロパン-2-イル)-4-(トリフルオロメチル)-[1,1'-ビフェニル]-2-イル]メチル}-4-メチル-1,3-オキサゾリジン-2-オン
• (4S,5R)-3-[5-(トリフルオロメチル)-2-(2-メトキシ-4-フルオロ-5-イソプロピルフェニル)ベンジル]-4-メチル-5-[3,5-ビス(トリフルオロメチル)フェニル]オキサゾリジン-2-オン